The idea that a longer duration of untreated psychosis (DUP) leads to poorer outcomes has
contributed to extensive changes in mental health services worldwide and has attracted …

Scientists have long sought to characterize the pathophysiologic basis of schizophrenia and
develop biomarkers that could identify the illness. Extensive postmortem and in vivo …

Treatments have been developed and tested to successfully reduce the symptoms and
disabilities of many mental illnesses. Unfortunately, people distressed by these illnesses …

BackgroundDuration of untreated psychosis (DUP) is one of the few potentially modifiable
predictors of outcomes of schizophrenia. Long DUP as a predictor of poor short-term …

Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults
across different stages, phases, and symptom domains. Method: Guidelines were developed …

Objective: Our primary aims were (a) to identify the proportion of individuals with
schizophrenia and related psychoses who met recovery criteria based on both clinical and …

Summary Background China and India jointly account for 38% of the world population, so
understanding the burden attributed to mental, neurological, and substance use disorders …

The lifespan of people with severe mental illness (SMI) is shorter compared to the general
population. This excess mortality is mainly due to physical illness. We report prevalence …

Background Three out of four first-episode psychosis (FEP) patients achieve clinical
remission following treatment. Unfortunately, functional recovery lags behind symptomatic …

Schizophrenia is the eighth leading cause of disability worldwide in people aged 15–44
years. Before antidopaminergic antipsychotics were introduced in the 1950s, no effective …